Tomoki Nishikawa
Overview
Explore the profile of Tomoki Nishikawa including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
18
Citations
84
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kimura M, Nishikawa T, Shimakami T, Terashima T, Horii R, Fukuda M, et al.
Glob Health Med
. 2025 Jan;
6(6):404-415.
PMID: 39741996
Hepatitis B and C (HBV and HCV) testing has been performed in Japan since 2002 and is subsidized by central and prefectural governments. A follow-up program for HBV- or HCV-infected...
2.
Yoshita M, Funaki M, Shimakami T, Kakuya M, Murai K, Sugimoto S, et al.
Viruses
. 2024 Aug;
16(8).
PMID: 39205320
We developed a novel hepatitis B virus (HBV) infection-monitoring system using a luminescent, 11-amino acid reporter (HiBiT). We performed high-throughput antiviral screening using this system to identify anti-HBV compounds. After...
3.
Yamada C, Kuwabara A, Sakai Y, Okuno C, Mine A, Misaki S, et al.
J Nutr Sci Vitaminol (Tokyo)
. 2024 Jan;
69(6):435-443.
PMID: 38171816
The Vitamin D Deficiency Questionnaire for Japanese (VDDQ-J) has been developed as an alternative indicator of the vitamin D nutritional status when serum 25(OH)D measurement is unavailable. In the present...
4.
Maeda-Minami A, Nishikawa T, Ishikawa H, Mutoh M, Makishima Y, Matsuyama Y, et al.
Anticancer Res
. 2023 Nov;
43(12):5629-5636.
PMID: 38030194
Background/aim: We previously reported a decrease in prostate-specific antigen (PSA) levels in patients with castration-resistant prostate cancer treated with angiotensin II receptor blockers (ARBs). However, no studies have reported the...
5.
Maeda-Minami A, Nishikawa T, Ishikawa H, Mutoh M, Akimoto K, Matsuyama Y, et al.
Genes Environ
. 2023 Oct;
45(1):25.
PMID: 37848957
Background: Prostate cancer is one of the most common cancers among men worldwide and the fourth most common cause of death. The number of prostate cancer cases and deaths is...
6.
Li Y, Kuroki K, Shimakami T, Murai K, Kawaguchi K, Shirasaki T, et al.
Cell Mol Gastroenterol Hepatol
. 2022 Oct;
15(3):533-558.
PMID: 36270602
Background & Aims: Hepatitis B virus (HBV) infection is difficult to cure owing to the persistence of covalently closed circular viral DNA (cccDNA). We performed single-cell transcriptome analysis of newly...
7.
Sumiyadorj A, Murai K, Shimakami T, Kuroki K, Nishikawa T, Kakuya M, et al.
Hepatol Commun
. 2022 Jun;
6(9):2441-2454.
PMID: 35691027
For the development of antiviral agents to eliminate hepatitis B virus (HBV), it is essential to establish an HBV cell culture system that can easily monitor HBV infection. Here, we...
8.
Enomoto A, Mano Y, Kawano Y, Nishikawa T, Aoyama T, Sasaki Y, et al.
Biol Pharm Bull
. 2021 Sep;
44(9):1294-1302.
PMID: 34471057
Direct oral anticoagulants (DOACs) are widely used for the prevention of ischemic stroke and systemic embolism in patients with nonvalvular atrial fibrillation (NVAF). However, the differences in safety and effectiveness...
9.
Kawano Y, Nagata M, Nakamura S, Akagi Y, Suzuki T, Tsukada E, et al.
Biol Pharm Bull
. 2021 May;
44(5):611-619.
PMID: 33952817
Oral anticoagulants (OACs) pose a major bleeding risk, which may be increased or decreased by concomitant medications. To explore medications that affect the bleeding risk of OACs, we conducted a...
10.
Nishikawa T, Nagata N, Shimakami T, Shirakura T, Matsui C, Ni Y, et al.
Sci Rep
. 2020 Jan;
10(1):815.
PMID: 31965018
Hyperuricemia drives the development of nonalcoholic fatty liver disease (NAFLD). Pharmacological inhibition of xanthine oxidase (XO), a rate-limiting enzyme for uric acid (UA) production, has been demonstrated to improve hepatic...